<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871466</url>
  </required_header>
  <id_info>
    <org_study_id>8.2016</org_study_id>
    <nct_id>NCT02871466</nct_id>
  </id_info>
  <brief_title>Stem Cells Therapy in Advanced Heart Failure</brief_title>
  <official_title>Intra Cardiac Autologous Stem Cells Infusion May Improve Clinical Outcomes in Failing Heart Subjects Refractory to Maximal Drug Therapy and Internal Cardioverter With a Defibrillator (ICD) Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second University of Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second University of Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      stem cells therapy may be a choice therapy for advanced heart failure patients refractory to
      medical therapy, internal cardiovertor with a defibrillator (ICD) recipients, and a previous
      history of myocardial infarction and coronary artery revascularization. These patients,
      without indication to receive a cardiac resynchronization therapy (CRT), may have a
      worsening of heart failure, and symptoms of coronary artery disease. In this study we have
      evaluated in consecutive 30 selected patients the amelioration in failing heart NYHA class,
      hospitalization rate, echocardiographic left ventricle functionality, and associated to
      reduction of angina after a treatment with stem cells intra thoracic infusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NYHA class improvement</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>reduction in hospitalization rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>reduction in angor symptoms</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>stem cells infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stem cells infusion</intervention_name>
    <arm_group_label>stem cells infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  heart failure post coronary artery disease, refractory to maximal medical therapy,
             previous coronary artery surgical revascularization.

        Exclusion Criteria:

          -  inflammatory chronic diseases, neoplastic diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 18, 2016</lastchanged_date>
  <firstreceived_date>August 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second University of Naples</investigator_affiliation>
    <investigator_full_name>Celestino Sardu</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
